189 related articles for article (PubMed ID: 30571684)
1. T-type calcium channel enhancer SAK3 promotes dopamine and serotonin releases in the hippocampus in naive and amyloid precursor protein knock-in mice.
Wang S; Yabuki Y; Matsuo K; Xu J; Izumi H; Sakimura K; Saito T; Saido TC; Fukunaga K
PLoS One; 2018; 13(12):e0206986. PubMed ID: 30571684
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological properties of SAK3, a novel T-type voltage-gated Ca
Yabuki Y; Matsuo K; Izumi H; Haga H; Yoshida T; Wakamori M; Kakei A; Sakimura K; Fukuda T; Fukunaga K
Neuropharmacology; 2017 May; 117():1-13. PubMed ID: 28093211
[TBL] [Abstract][Full Text] [Related]
3. The T-type calcium channel enhancer SAK3 inhibits neuronal death following transient brain ischemia via nicotinic acetylcholine receptor stimulation.
Yabuki Y; Jing X; Fukunaga K
Neurochem Int; 2017 Sep; 108():272-281. PubMed ID: 28457878
[TBL] [Abstract][Full Text] [Related]
4. T-type calcium channel enhancer SAK3 produces anti-depressant-like effects by promoting adult hippocampal neurogenesis in olfactory bulbectomized mice.
Xu J; Yabuki Y; Yu M; Fukunaga K
J Pharmacol Sci; 2018 Aug; 137(4):333-341. PubMed ID: 30196018
[TBL] [Abstract][Full Text] [Related]
5. SAK3 Administration Improves Spine Abnormalities and Cognitive Deficits in App
Izumi H; Kawahata I; Shinoda Y; Helmstetter FJ; Fukunaga K
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32481611
[TBL] [Abstract][Full Text] [Related]
6. Single Administration of the T-Type Calcium Channel Enhancer SAK3 Reduces Oxidative Stress and Improves Cognition in Olfactory Bulbectomized Mice.
Yuan D; Cheng A; Kawahata I; Izumi H; Xu J; Fukunaga K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33451040
[TBL] [Abstract][Full Text] [Related]
7. T-Type Ca
Xu J; Kawahata I; Izumi H; Fukunaga K
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201181
[TBL] [Abstract][Full Text] [Related]
8. [Role of T-type Calcium Channels in Regulating Neuronal Function].
Yabuki Y
Yakugaku Zasshi; 2020; 140(10):1207-1212. PubMed ID: 32999199
[TBL] [Abstract][Full Text] [Related]
9. Acute Treatment with T-Type Calcium Channel Enhancer SAK3 Reduces Cognitive Impairments Caused by Methimazole-Induced Hypothyroidism Via Activation of Cholinergic Signaling.
Husain N; Yabuki Y; Shinoda Y; Fukunaga K
Pharmacology; 2018; 101(5-6):309-321. PubMed ID: 29597200
[TBL] [Abstract][Full Text] [Related]
10. The Disease-modifying Drug Candidate, SAK3 Improves Cognitive Impairment and Inhibits Amyloid beta Deposition in App Knock-in Mice.
Izumi H; Shinoda Y; Saito T; Saido TC; Sato K; Yabuki Y; Matsumoto Y; Kanemitsu Y; Tomioka Y; Abolhassani N; Nakabeppu Y; Fukunaga K
Neuroscience; 2018 May; 377():87-97. PubMed ID: 29510211
[TBL] [Abstract][Full Text] [Related]
11. T-type Ca
Degawa T; Kawahata I; Izumi H; Shinoda Y; Fukunaga K
J Pharmacol Sci; 2021 May; 146(1):1-9. PubMed ID: 33858649
[TBL] [Abstract][Full Text] [Related]
12. The investigation of the T-type calcium channel enhancer SAK3 in an animal model of TAF1 intellectual disability syndrome.
Janakiraman U; Dhanalakshmi C; Yu J; Moutal A; Boinon L; Fukunaga K; Khanna R; Nelson MA
Neurobiol Dis; 2020 Sep; 143():105006. PubMed ID: 32622085
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effects of the T-type calcium channel enhancer SAK3 in a rat model of TAF1 deficiency.
Dhanalakshmi C; Janakiraman U; Moutal A; Fukunaga K; Khanna R; Nelson MA
Neurobiol Dis; 2021 Feb; 149():105224. PubMed ID: 33359140
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's disease therapeutic candidate SAK3 is an enhancer of T-type calcium channels.
Fukunaga K; Izumi H; Yabuki Y; Shinoda Y; Shioda N; Han F
J Pharmacol Sci; 2019 Feb; 139(2):51-58. PubMed ID: 30600144
[TBL] [Abstract][Full Text] [Related]
15. Novel cognitive enhancer ST101 enhances acetylcholine release in mouse dorsal hippocampus through T-type voltage-gated calcium channel stimulation.
Yamamoto Y; Shioda N; Han F; Moriguchi S; Fukunaga K
J Pharmacol Sci; 2013; 121(3):212-26. PubMed ID: 23449490
[TBL] [Abstract][Full Text] [Related]
16. Expression of Concern: T-type calcium channel enhancer SAK3 promotes dopamine and serotonin releases in the hippocampus in naive and amyloid precursor protein knock-in mice.
PLOS ONE Editors
PLoS One; 2023; 18(1):e0280120. PubMed ID: 36630395
[No Abstract] [Full Text] [Related]
17. Correction: T-type calcium channel enhancer SAK3 promotes dopamine and serotonin releases in the hippocampus in naive and amyloid precursor protein knock-in mice.
Wang S; Yabuki Y; Matsuo K; Xu J; Izumi H; Sakimura K; Saito T; Saido TC; Fukunaga K
PLoS One; 2019; 14(1):e0211590. PubMed ID: 30682166
[TBL] [Abstract][Full Text] [Related]
18. Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus.
Huang M; Li Z; Dai J; Shahid M; Wong EH; Meltzer HY
Neuropsychopharmacology; 2008 Nov; 33(12):2934-45. PubMed ID: 18418367
[TBL] [Abstract][Full Text] [Related]
19. The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens.
Huang M; Felix AR; Flood DG; Bhuvaneswaran C; Hilt D; Koenig G; Meltzer HY
Psychopharmacology (Berl); 2014 Dec; 231(23):4541-51. PubMed ID: 24810107
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
